Answers are grounded in this paper and cite their sources.
While immune checkpoint inhibitors (ICIs) benefit patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC), most with microsatellite stable (MSS) disease are unresponsive. Caspase-6 (CASP6) is implicated in apoptosis and other processes, but its role as a biomarker in colorectal cancer (CRC) and the tumor immune microenvironment (TIME) remains unclear and contradictory. We combined bioinformatics and in vitro validation. CASP6’s clinical significance was analyzed using TCGA/HPA data. The effects of CASP6 knockdown via siRNA were assessed in HCT116 and Caco2 cells (proliferation, migration, apoptosis). Underlying mechanisms regarding the TIME and immunotherapy response were explored via GSEA, immune deconvolution (CIBERSORT, ESTIMATE), and immunophenoscore (IPS) analysis. CASP6 was downregulated in CRC tissues, and low mRNA expression correlated with poorer overall and progression-free survival. To dissect this clinical observation, we performed in vitro functional assays. Paradoxically, CASP6 knockdown suppressed cancer cell proliferation and migration while inducing apoptosis in vitro, suggesting a pro-tumorigenic role at the cellular level. However, this cell-intrinsic oncogenic effect contrasts with its role in the tumor microenvironment. Bioinformatics revealed that tumors with low CASP6 mRNA levels exhibited an immunosuppressive TIME, characterized by increased regulatory T-cell infiltration and elevated expression of immune checkpoints (PD-L1, CTLA-4). This suggests that the reduced CASP6 expression, while inhibiting cell-autonomous malignancy, may facilitate immune escape. Consequently, these tumors also had a higher IPS, predicting a better potential response to anti-PD-1/CTLA-4 therapy. This study reveals a dual role for CASP6: it promotes tumor cell malignancy cell-autonomously, yet its expression may enhance immunogenicity. Downregulation of CASP6 may represent an immune escape mechanism potentially driven by immunoediting, explaining its association with poor prognosis but also a more favorable immunotherapy context. Thus, CASP6 mRNA expression is a promising biomarker for stratifying CRC patients.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: